Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin
Authors:
- 4 May 2022
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 22 (6) , 597-603
Abstract
Neuroendocrine carcinomas are very aggressive tumors with few treatment options. DLL3 seems to be an optimal target for therapeutic intervention, as it is expressed mainly on the membrane of tumor ...Keywords
This publication has 63 references indexed in Scilit:
- Different assemblies of Notch receptors coordinate the distribution of the major bronchial Clara, ciliated and neuroendocrine cellsDevelopment, 2012
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC studyAnnals of Oncology, 2012
- Regulation of Notch1 Signaling by Delta-like Ligand 1 Intracellular Domain through Physical InteractionMolecules and Cells, 2011
- Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosisHuman Molecular Genetics, 2010
- Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathwayOncogene, 2010
- Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivoJournal of Cell Biology, 2007
- Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine TumorsThe Oncologist, 2007
- Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cellsSurgery, 2005
- CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor ImmunotherapyAnnual Review of Immunology, 2001
- CTLA-4 Regulates Induction of Anergy In VivoImmunity, 2001